ArticleNeurologia medico-chirurgica2026
Impact of Metabolic Syndrome Components on Early Outcomes after Aneurysmal Subarachnoid Hemorrhage.
Article in Neurologia medico-chirurgica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aneurysmal subarachnoid hemorrhage remains a devastating condition with persistently high rates of early mortality and disability. While numerous prognostic models exist, the prognostic relevance of metabolic dysfunction in aneurysmal subarachnoid hemorrhage remains uncertain. We retrospectively analyzed 60 consecutive patients with subarachnoid hemorrhage admitted between 2022 and 2024. Metabolic syndrome and its components-including impaired glucose tolerance, insulin resistance, hypertension, dyslipidemia, and obesity-were evaluated within 24 hours of admission. The primary endpoint was poor functional outcome at discharge (modified Rankin Scale 3-6). Secondary endpoints included in-hospital complications and mortality. In adjusted ridge-penalized logistic regression analyses, impaired glucose tolerance (adjusted odds ratio 4.93, 95% confidence interval 1.39-17.4, p = 0.014) and World Federation of Neurological Surgeons grade ≥3 (adjusted odds ratio 5.12, 95% confidence interval 1.62-16.18, p = 0.006) independently predicted poor outcome. Insulin resistance was independently associated with in-hospital complications (adjusted odds ratio 4.05, 95% confidence interval 1.15-14.3, p = 0.030). Mortality was independently predicted by age (adjusted odds ratio 1.06, 95% confidence interval 1.01-1.12, p = 0.032), World Federation of Neurological Surgeons grade ≥3, and impaired glucose tolerance. The composite metabolic syndrome variable was not an independent predictor of any outcome. In conclusion, specific metabolic abnormalities- impaired glucose tolerance, insulin resistance, and hypertension-rather than metabolic syndrome appear to drive early prognosis after subarachnoid hemorrhage. Early metabolic profiling and individualized glucose control may help identify patients at risk and guide future interventional studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.